Overview of Development and Formulation of ¹⁷⁷Lu-DOTA-TATE for PRRT

Title:Overview of Development and Formulation of ¹⁷⁷Lu-DOTA-TATE for PRRT

Volume: 9 Issue: 1

Author(s): Wouter A.P. Breeman, Ho Sze Chan, Rory M.S. de Zanger, Mark K. Konijnenberg and Erik de Blois

Affiliation:

Keywords: 177Lu-DOTA-TATE, DOTANOC, DOTATOC, DOTA-TATE, PRRT, radiochemistry, formulation.

Abstract: Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs has become an established procedure for the treatment of patients suffering from inoperable neuroendocrine cancers over-expressing somatostatin receptors. Success of PRRT depends on the availability of the radiolabeled peptide with adequately high specific activity, so that required therapeutic efficacy can be achieved without saturating the limited number of receptors available on the target lesions. Specific activity of the radionuclide and the radiolabeled somatostatin analog are therefore an important parameters. Although these analogs have been investigated and improved, and successfully applied for PRRT for more than 15 years, there are still many possibilities for further improvements that fully exploit PRRT with ¹⁷⁷Lu-DOTA-TATE.

The here summarized data presented herein on increased knowledge of the components of ¹⁷⁷Lu-DOTA-TATE (especially the purity of ¹⁷⁷Lu and specific activity of ¹⁷⁷Lu) and the reaction kinetics during labeling ¹⁷⁷Lu-DOTA-TATE clearly show that the peptide dose and dose in GBq can be varied.

Here we present an overview of the development, formulation and optimisation of ¹⁷⁷Lu-DOTA-TATE, mainly addressing radiochemical parameters

Cite this article as:

Breeman A.P. Wouter, Chan Sze Ho, de Zanger M.S. Rory, Konijnenberg K. Mark and Blois de Erik, Overview of Development and Formulation of ¹⁷⁷Lu-DOTA-TATE for PRRT, Current Radiopharmaceuticals 2016; 9 (1) . https://dx.doi.org/10.2174/1874471008666150313111131